A phase II study of limited resection for the patient having pulmonary adenocarcinoma with groung glass opacity selected by HR-CT and PET findings
- Conditions
- pulmonary adenocarcinoma with ground glass opacity
- Registration Number
- JPRN-UMIN000005908
- Lead Sponsor
- Japanese Northern East Area Thoracic Surgery Study Group (JNETS)
- Brief Summary
From November 2006 to April 2012, 73 patients were collected from 13 institutions. One patient was ineligible and remaining 72 patients were pre-registered. The tumors of 3 and 14 cases were intraoperatively diagnosed as benign lesions and adenocarcinomas with mixed subtype, respectively. Intraoperative cytological/histological examination of surgical margin was not performed in 2 cases, and remaining 53 patients were ultimately eligible for this study. The mean tumour size was 14.0 mm and the mean GGO ratio was 95.9%. Thirty-nine and 14 patients underwent wedge resection and segmentectomy, respectively. Although all tumors were intraoperatively diagnosed as bronchioloalveolar carcinomas, 6 were ultimately diagnosed as adenocarcinoma with mixed subtype. No completion lobectomy was performed. As of May 1, 2017, no recurrence of the original lung cancer was observed during 60.0-126.3 months after surgery. Two patients died from other diseases. The 5-year disease-specific and overall survival rates were 100% and 98.1%, respectively. The reduction in the pulmonary function after limited resection was minimal. With these criteria, limited resection was performed safely without any recurrence, and the postoperative pulmonary function was well-preserved. The outcomes of limited resection for small-sized lung cancer with GGOs that met the criteria of this study were satisfactory.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 53
Not provided
multiple cancer within 5 years preoperative treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 5-year survival rate
- Secondary Outcome Measures
Name Time Method proportion of local recurrence, relapse-free survival, changes of the pulmonary function